Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation.

MLA

Major-Monfried, Hannah, et al. “Two Novel Assays Demonstrate Persistent Daratumumab Exposure in a Pediatric Patient with Delayed Engraftment Following Allogeneic Hematopoietic Stem Cell Transplantation.” Cytotherapy, vol. 26, no. 5, May 2024, pp. 466–71. EBSCOhost, https://doi.org/10.1016/j.jcyt.2024.01.005.

APA

Major-Monfried, H., Hosszu, K., McAvoy, D. P., Vallone, A., Shukla, N., Gillio, A., Spitzer, B., Kung, A. L., Cancio, M., Curran, K., Scaradavou, A., Oved, J. H., O’Reilly, R. J., Boelens, J. J., & Harris, A. C. (2024). Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation. Cytotherapy, 26(5), 466–471. https://doi.org/10.1016/j.jcyt.2024.01.005

Chicago

Major-Monfried, Hannah, Kinga Hosszu, Devin P McAvoy, Alexander Vallone, Neerav Shukla, Alfred Gillio, Barbara Spitzer, et al. 2024. “Two Novel Assays Demonstrate Persistent Daratumumab Exposure in a Pediatric Patient with Delayed Engraftment Following Allogeneic Hematopoietic Stem Cell Transplantation.” Cytotherapy 26 (5): 466–71. doi:10.1016/j.jcyt.2024.01.005.